Economic burden of antibiotic resistance: how much do we really know?

被引：172
|
作者：
Gandra, S. [1 ]
Barter, D. M. [1 ]
Laxminarayan, R. [1 ,2 ,3 ]
机构：
[1] Ctr Dis Dynam Econ & Policy, Washington, DC USA
[2] Publ Hlth Fdn India, New Delhi 110017, India
[3] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2014年 / 20卷 / 10期
基金：
比尔及梅琳达.盖茨基金会;
关键词：
Antibiotic resistance; attributable morbidity and mortality; economics; LENGTH-OF-STAY; SUSCEPTIBLE STAPHYLOCOCCUS-AUREUS; SPECTRUM BETA-LACTAMASES; BLOOD-STREAM INFECTIONS; TIME-DEPENDENT BIAS; NOSOCOMIAL METHICILLIN-RESISTANT; ANTIMICROBIAL RESISTANCE; HEALTH-CARE; ACINETOBACTER-BAUMANNII; HOSPITAL STAY;
D O I：
10.1111/1469-0691.12798
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual effect of antibiotic resistance on clinical outcomes is a necessary first step. In this article, we review and discuss the contributions and limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic resistance.
引用
收藏
页码：973 / 980
页数：8
相关论文
共 50 条
12345